Insys Plans $29M CBD And Naloxone Sale In Ch. 11

By Chris Villani · August 9, 2019, 3:13 PM EDT

Embattled and bankrupt drugmaker Insys Therapeutics Inc. has entered into agreements to sell the company's naloxone spray and cannabis-based products to a pair of companies for a total of $29 million,...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Case Information

Case Title

Insys Therapeutics, Inc.

Case Number

Court

Delaware

Nature of Suit

Date Filed

June 10, 2019

Recent Articles By Chris

July 23, 2024
'Surface Water' Stumps Mass. Justices In Loss For Insurers
July 12, 2024
Feds Say Fake Gunshot Wounds Part Of $1M Fraud Scheme
March 01, 2024
GSK, Shook Hardy Can Recover Costs After Zofran MDL Win
February 26, 2024
Teva Tells 1st Circ. Feds Must Clear High Bar In FCA Case
February 20, 2024
Justices Decline Malpractice Dispute Over $6M Settlement
December 21, 2023
The 5 Biggest First Circuit Rulings Of 2023
December 20, 2023
No Discovery In Regeneron FCA Case Until 1st Circ. Rules
November 21, 2023
Ex-Aegerion Rep Cops To Fraud, Avoiding Trial Redo
November 13, 2023
Florida Duo Cops To $1.5M Medicare Fraud In Ga. Court
November 13, 2023
Ex-Aegerion Rep. Strikes Deal To Avoid 2nd Fraud Trial